Hongling Peng

Professor Peng Hongling, 45, the current director of Hematology Department, chief physician and doctoral supervisor, has worked in the field of Hematology, especially in the field of targeted therapy and molecular mechanism of lymphocytic leukemia for nearly 20 years. He studied at the Dana Farber Cancer Institute of Harvard Medical School and studied with Professor A Thomas look, also known as "the father of zebrafish". After returning to China, the first zebrafish platform of Central South University was established. Based on this platform, the construction of the lymphocytic leukemia transgenic model and drug intervention research was completed, and the gene function of the zebrafish model was studied in combination with CRISPR / cas9 gene-editing technology. He has worked and studied in the National Natural Science Foundation of China, presided over three National Natural Science Foundation and three provincial and ministerial scientific research projects, and published more than 20 SCI papers in total. The first author published his works in the Journal of the American Society of Hematology "J throm hemat" and published his papers in the journal "leukemia" and "Lancet" as the main author, He published his works as a corresponding author in the famous journal "cancer communication" in the field of cancer research. He served as the leader of Hunan chronic lymphoblastic leukemia (CLL) cooperation group, the first provincial CLL group in China, and led the development of CLL in Hunan Province; He actively promoted and established the hematology branch of Hunan Geriatrics Association and served as the executive vice-chairman and secretary-general. As the first adult, he won the second prize of new medical technology of Central South University in 2016 and the first prize of new medical technology of Xiangya Second Hospital. He promoted the development of clinical and scientific research. He is an influential middle-aged and young expert in hematology in China.